New drug cocktail aims to shrink HER2+ stomach tumors before surgery
NCT ID NCT05034887
First seen Apr 09, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests whether a combination of targeted drugs (trastuzumab deruxtecan, capecitabine, and durvalumab) can shrink HER2-positive stomach or gastroesophageal junction cancer before surgery and prevent return after surgery. About 64 adults with untreated, advanced but not spread cancer will participate. The main goal is to see how many patients have little to no tumor left after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Conditions
Explore the condition pages connected to this study.